ライフサイエンスコーパス: indoleamine 2,3-dioxygenase

1 duces depressive-like behavior by activating indoleamine 2,3 dioxygenase.

2 were evaluated for their ability to inhibit indoleamine 2,3-dioxygenase.

3 the presence of H(2)O(2)/ONOO(-) deactivated indoleamine 2,3-dioxygenase.

4 of 2',5'-oligoadenylate synthetase, Mx1, and indoleamine 2,3-dioxygenase.

5 cells through the induction and activity of indoleamine 2,3-dioxygenase.

6 a induces expression of p47 GTPases, but not indoleamine 2,3-dioxygenase.

7 hyl-tryptophan which is also an inhibitor of indoleamine 2,3-dioxygenase.

8 t in vitro (though not in vivo) inhibitor of indoleamine 2,3-dioxygenase.

9 eam target, the tryptophan-catalyzing enzyme indoleamine 2,3-dioxygenase.

10 eries of substituted tryptophan analogues by indoleamine 2,3-dioxygenase.

11 ited T-cell reactivity through regulation of indoleamine-2,3-dioxygenase.

12 ulatory molecules including IL-10, CD25, and indoleamine-2,3-dioxygenase.

13 xpression of the tryptophan-degrading enzyme indoleamine-2,3-dioxygenase.

14 tryptophan via the IFN-gamma-induced enzyme indoleamine 2, 3-dioxygenase.

15 was not mediated via induction of the enzyme indoleamine 2, 3-dioxygenase.

16 Indoleamine 2, 3-dioxygenase 1 (IDO) catalyzes 1 rate-li

17 endent on the tryptophan catabolizing enzyme indoleamine 2,3 dioxygenase 1 (IDO1) in splenic macropha

18 Indoleamine 2,3 dioxygenase 1 (IDO1) is an attractive ta

19 The tryptophan-metabolizing enzyme indoleamine 2,3 dioxygenase 1 (IDO1) is frequently overe

20 Human indoleamine 2,3-dioxygenase 1 (hIDO1) and human tryptoph

21 Indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan dio

22 Human indoleamine 2,3-dioxygenase 1 (hIDO1) is an attractive c

23 sion protein of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO) and galectin-3 (Gal3

24 involved in atherogenic responses, including Indoleamine 2,3-Dioxygenase 1 (IDO1) and Stimulator of I

25 Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-

26 nd, thus, the Kyn pathway and its key player indoleamine 2,3-dioxygenase 1 (IDO1) are appealing targe

27 Since the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) as an attractive ta

28 During systemic inflammation, indoleamine 2,3-dioxygenase 1 (IDO1) becomes expressed i

29 ses of two antiretroviral ISGs indicate that indoleamine 2,3-dioxygenase 1 (IDO1) can inhibit retrovi

30 Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the rate-

31 as driven by IFN-gamma-mediated induction of indoleamine 2,3-dioxygenase 1 (IDO1) enzyme activity wit

32 ular tryptophan shortage by upregulating the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme(1-4).

33 ession of the tryptophan metabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1) in the intestinal e

34 Indoleamine 2,3-dioxygenase 1 (IDO1) is a key regulatory

35 Indoleamine 2,3-dioxygenase 1 (IDO1) is a single chain o

36 ic pathway (KYNPATH) initiated by the enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is ablated pharmaco

37 Indoleamine 2,3-dioxygenase 1 (IDO1) is an important the

38 ding l-kynurenine (Kyn), the main product of indoleamine 2,3-dioxygenase 1 (IDO1) that catalyzes the

39 d that S. flexneri induces the expression of indoleamine 2,3-dioxygenase 1 (IDO1) through the nucleot

40 Here, we report that brain indoleamine 2,3-dioxygenase 1 (IDO1), a rate-limiting en

41 activation of the non-enzymatic functions of indoleamine 2,3-dioxygenase 1 (IDO1), an immunoregulator

42 tion, a host tryptophan-catabolizing enzyme, indoleamine 2,3-dioxygenase 1 (IDO1), is induced specifi

43 Indoleamine 2,3-dioxygenase 1 (IDO1), promoting immune e

44 s along the kynurenine pathway by the enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which is induced b

45 ystemic inflammation only in the presence of indoleamine 2,3-dioxygenase 1 (IDO1).

46 oxP3(+) regulatory T-cells (Tregs), CD47 and indoleamine 2,3-dioxygenase 1 (IDO1).

47 ndoles are described as potent inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1).

48 asmid against the immunosuppressive molecule indoleamine 2,3-dioxygenase 1 (shIDO).

49 Tryptophan catabolism by the enzymes indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxyge

50 hermore, treatment of NKp44(+) NK cells with indoleamine 2,3-dioxygenase 1 catabolites in vitro ablat

51 However, whether indoleamine 2,3-dioxygenase 1 forms (1)O(2) and whether

52 Here we show that arterial indoleamine 2,3-dioxygenase 1 regulates blood pressure v

53 lysed by a family of dioxygenases, including indoleamine 2,3-dioxygenase 1(5).

54 Indoleamine 2,3-dioxygenase 1, a catabolic enzyme, and i

55 ocarbon receptor that, activated through the indoleamine 2,3-dioxygenase 1-kynurenine pathway, transc

56 inflammatory mediators in the gut, including indoleamine 2,3-dioxygenase 1.

57 Indoleamine 2,3 dioxygenase-1 (IDO-1) is an enzyme in th

58 Indoleamine 2,3 dioxygenase-1 (IDO1) catabolizes tryptop

59 Indoleamine 2,3 dioxygenase-1 (IDO1) catalyzes tryptopha

60 y are associated with elevated expression of indoleamine 2,3 dioxygenase-1 (IDO1).

61 depend on inflammation-induced activation of indoleamine 2,3 dioxygenase-1 (IDO1).

62 munodeficiency virus (HIV) infection-induced indoleamine 2,3-dioxygenase-1 (IDO) expression in activa

63 rominent immunotherapeutic targets OX40L and indoleamine 2,3-dioxygenase-1 (IDO), to tumours in vivo.

64 Small-molecule inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) are emerging at the

65 We report the discovery of a novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor class thr

66 nd human studies have demonstrated that host indoleamine 2,3-dioxygenase-1 (IDO1) is upregulated in r

67 Indoleamine 2,3-dioxygenase-1 (IDO1; IDO) mediates oxida

68 ols, whereas level of messenger RNA encoding indoleamine 2,3-dioxygenase-1 was significantly increase

69 Elevated betaDG correlated positively with indoleamine-2,3-dioxygenase-1 enzyme activity, regulator

70 , the SE inhibited the enzymatic activity of indoleamine 2,3 dioxygenase, a key enzyme in immune tole

71 n-gamma-induced degradation of tryptophan by indoleamine 2,3-dioxygenase, activates the previously or

72 Increased indoleamine 2,3-dioxygenase activity and consequent indu

73 cts of gamma interferon (IFN-gamma)-mediated indoleamine 2,3-dioxygenase activity on C. pneumoniae pe

74 The indoleamine 2,3-dioxygenase activity was assessed by mas

75 cells, possibly via stimulation of host cell indoleamine-2,3-dioxygenase activity, in a dose-dependen

76 e, is similar to that of the large domain of indoleamine 2,3-dioxygenase, an enzyme that catalyzes th

77 lls express high levels of CD163, CD206, and indoleamine 2,3-dioxygenase and secrete immunosuppressiv

78 grafts and increased expression of mRNAs for indoleamine 2,3-dioxygenase and the subunits encoding in

79 Despite its structural similarity to indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygena

80 is an O2-dependent process and catalyzed by indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygena

81 g induction was mediated by DC expression of indoleamine 2,3-dioxygenase, and was confirmed in IDO-KO

82 w) phenotype, expressed the immunomodulatory indoleamine-2,3-dioxygenase, and upregulated expression

83 of various tumor-promoting genes, including indoleamine 2,3-dioxygenase; and attenuation of these ch

84 ot reverse tolerance, but treatment with the indoleamine-2,3-dioxygenase antagonist 1-methyltryptopha

85 expression of tolerogenic mediators, such as indoleamine-2,3-dioxygenase, arginase, and TGF-beta, and

86 With TDO and Indoleamine 2,3-dioxygenase as evolutionarily conserved

87 Inhibition of placental indoleamine 2,3-dioxygenase by 1-methyl-tryptophan preve

88 sistent with a common reaction mechanism for indoleamine 2,3-dioxygenase-catalyzed oxidation of trypt

89 Indoleamine 2,3-dioxygenase catalyzes the O(2)-dependent

90 r- beta 1+ cells, interleukin-10+ cells, and indoleamine 2,3-dioxygenase+CD3+ cells.

91 Potential roles for indoleamine 2,3-dioxygenase, costimulatory molecules, an

92 In summary, increasing indoleamine 2,3 dioxygenase-derived kynurenine level pro

93 physiological importance of human placental indoleamine 2,3-dioxygenase (EC 1.13.11.42), the first a

94 lation of circulating prostaglandin E(2) and indoleamine 2, 3,-dioxygenase enzymatic activity, as wel

95 IL-27-induced indoleamine 2,3-dioxygenase enzymatic activity leads to

96 but not sequence homology to the two-domain indoleamine 2,3-dioxygenase enzyme (IDO).

97 on an omega-3 fatty acid derivative inducing indoleamine 2,3-dioxygenase expression in DC.

98 In human epithelial cells, IFN-gamma induces indoleamine 2,3-dioxygenase expression that inhibits chl

99 feron-gamma, which increases villous explant indoleamine 2,3-dioxygenase expression, has no effect on

100 ve increased accumulation of CD11c cells and indoleamine 2,3-dioxygenase expression.

101 that inhibition of enzyme activity in human indoleamine 2,3-dioxygenase (hIDO) and a number of site-

102 Human indoleamine 2,3-dioxygenase (hIDO) is an intracellular h

103 Human indoleamine 2,3-dioxygenase (hIDO) is an intracellular h

104 han 2,3 dioxygenase (hTDO), and the other is indoleamine 2,3-dioxygenase (hIDO), both of which cataly

105 nt in heme-based dioxygenases, such as human indoleamine 2,3-dioxygenase (hIDO), was not recognized u

106 in humans: tryptophan dioxygenase (hTDO) and indoleamine 2,3-dioxygenase (hIDO).

107 teins, tryptophan 2,3-dioxygenase (hTDO) and indoleamine 2,3-dioxygenase (hIDO).

108 proved SB transposon encoding the human gene indoleamine-2,3-dioxygenase (hIDO), an enzyme that posse

109 HS suppressed mRNA and protein expression of indoleamine 2, 3-dioxygenase (IDO) and its activity upon

110 Production of indoleamine 2, 3-dioxygenase (IDO) by macrophages has re

111 recently shown that expression of the enzyme indoleamine 2, 3-dioxygenase (IDO) during murine pregnan

112 Indoleamine 2, 3-dioxygenase (IDO) is an immunoregulator

113 Furthermore, inhibition of indoleamine 2, 3-dioxygenase (IDO) resulted in decreased

114 y modulating the expression of PD-L1; Tim-3; indoleamine 2, 3-dioxygenase (IDO); and interleukin 10.

115 The enzyme indoleamine 2, 3-dioxygenase (IDO-1) initiates and regul

116 , depletion of Gr1(+) cells or inhibition of indoleamine 2,3 dioxygenase (IDO) activity abrogates gra

117 Indoleamine 2,3 dioxygenase (IDO) activity during pregna

118 Indoleamine 2,3 dioxygenase (IDO) and arginase 1 (ARG1),

119 amino acid TRP, cells expressing the enzyme indoleamine 2,3 dioxygenase (IDO) can mediate potent loc

120 Indoleamine 2,3 dioxygenase (IDO) catabolizes the amino

121 Indoleamine 2,3 dioxygenase (IDO) has emerged as an impo

122 d expression of the immune regulatory enzyme indoleamine 2,3 dioxygenase (IDO) in local lymph nodes.

123 Indoleamine 2,3 dioxygenase (IDO) is a catabolic enzyme

124 xpression of the tryptophan-degrading enzyme indoleamine 2,3 dioxygenase (IDO) is selectively induced

125 ha(-/-) mice was likely because of a lack of indoleamine 2,3 dioxygenase (IDO), a critical regulator

126 e expression of interferon-gamma (IFNgamma), indoleamine 2,3 dioxygenase (IDO), and human leukocyte a

127 local draining lymph nodes (dLNs) to express indoleamine 2,3 dioxygenase (IDO), which confers T cell

128 aneously, pDCs up-regulate the expression of indoleamine 2,3 dioxygenase (IDO), which is essential fo

129 The roles of anergy and the indoleamine 2,3 dioxygenase (IDO)-tryptophan pathway in

130 tivating immunoregulatory mechanisms such as indoleamine 2,3 dioxygenase (IDO).

131 ressive factors IL-4, IL-10, CD274/PD-L1 and indoleamine 2,3 dioxygenase (IDO).

132 Pharmacological inhibition of indoleamine 2,3-dioxygenase (IDO) activity during murine

133 ther gamma interferon (IFN-gamma) can induce indoleamine 2,3-dioxygenase (IDO) activity in aortic smo

134 higher levels of gamma interferon-inducible indoleamine 2,3-dioxygenase (IDO) activity than endothel

135 ike receptor (TLR) 4 signaling, can regulate indoleamine 2,3-dioxygenase (IDO) activity, favoring TH2

136 cells could be attributed to their increased indoleamine 2,3-dioxygenase (IDO) activity.

137 (IgM), cytokine/granzyme concentrations, and indoleamine 2,3-dioxygenase (IDO) activity.

138 describe a subset of human APCs that express indoleamine 2,3-dioxygenase (IDO) and inhibit T cell pro

139 h a focus on the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase (IDO) and its recently disco

140 ltiple immune inhibitory molecules including indoleamine 2,3-dioxygenase (IDO) and programmed cell de

141 inhibitory effect was primarily mediated by indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (

142 duction of anti-inflammatory factors such as indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (

143 omotes immune suppression through the enzyme indoleamine 2,3-dioxygenase (IDO) and subsequent product

144 tivated inflammatory macrophages can express indoleamine 2,3-dioxygenase (IDO) and thus actively depl

145 Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dio

146 ortage of tryptophan caused by expression of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dio

147 eprogramming was suppressed by tumor-induced indoleamine 2,3-dioxygenase (IDO) and vaccination failed

148 Small-molecule inhibitors of indoleamine 2,3-dioxygenase (IDO) are currently being tr

149 Human tryptophan dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO) are two important targ

150 Indoleamine 2,3-dioxygenase (IDO) catalyzes the breakdow

151 Indoleamine 2,3-dioxygenase (IDO) catalyzes the initial,

152 Tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO) constitute an importan

153 aneous efficacy of serum and urine biomarker indoleamine 2,3-dioxygenase (IDO) enzyme activity and pe

154 CR analysis revealed a 5-fold enhancement of indoleamine 2,3-dioxygenase (IDO) expression in the tumo

155 Additionally, indoleamine 2,3-dioxygenase (IDO) expression was only mo

156 Indoleamine 2,3-dioxygenase (IDO) has immunoregulatory r

157 vation of the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) in cancer cells facili

158 ously shown that an immunomodulatory enzyme, indoleamine 2,3-dioxygenase (IDO) in dermal fibroblasts

159 rucial role for the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) in GVHD regulation.

160 tent to express the T-cell regulatory enzyme indoleamine 2,3-dioxygenase (IDO) in mice treated with T

161 upregulated both the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) in plasmacytoid DCs an

162 critical role for the immune escape mediator indoleamine 2,3-dioxygenase (IDO) in supporting inflamma

163 Elevation of the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) in tumor cells can fac

164 n 4 (CTLA-4) blockade and treatment with the indoleamine 2,3-dioxygenase (IDO) inhibitor 1-methyl-D-t

165 n a prodrug conjugate of PEG with NLG919, an indoleamine 2,3-dioxygenase (IDO) inhibitor currently us

166 nt and include chemotherapeutics, radiation, indoleamine 2,3-dioxygenase (IDO) inhibitors, inhibitors

167 Indoleamine 2,3-dioxygenase (IDO) is a heme-containing d

168 Indoleamine 2,3-dioxygenase (IDO) is a heme-containing e

169 The heme enzyme indoleamine 2,3-dioxygenase (IDO) is a key regulator of

170 Indoleamine 2,3-dioxygenase (IDO) is a negative regulato

171 The immunosuppressive protein indoleamine 2,3-dioxygenase (IDO) is a rate-limiting enz

172 Indoleamine 2,3-dioxygenase (IDO) is a unique cytosolic

173 Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressiv

174 bolism of the amino acid tryptophan (Trp) by indoleamine 2,3-dioxygenase (IDO) is considered an impor

175 Indoleamine 2,3-dioxygenase (IDO) is emerging as an impo

176 The immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) is expressed by a subs

177 The immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) is expressed by APCs a

178 The tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) is expressed in macrop

179 y, expression of the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) is induced following i

180 Indoleamine 2,3-dioxygenase (IDO) is one molecular mecha

181 Indoleamine 2,3-dioxygenase (IDO) is the enzyme that cat

182 Indoleamine 2,3-dioxygenase (IDO) is the first and rate-

183 Indoleamine 2,3-dioxygenase (IDO) is the first and rate-

184 Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting e

185 Here, we examine the inhibitory role of indoleamine 2,3-dioxygenase (IDO) on the antitumor effic

186 well as interfering in the immunosuppressive indoleamine 2,3-dioxygenase (IDO) pathway.

187 Tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO) play a central role in

188 The heme enzyme indoleamine 2,3-dioxygenase (IDO) plays an important imm

189 ors of the tryptophan (Trp) catabolic enzyme indoleamine 2,3-dioxygenase (IDO) represent a vanguard o

190 Dendritic cell-derived indoleamine 2,3-dioxygenase (IDO) suppresses naive T cel

191 s study, we investigated the relationship of indoleamine 2,3-dioxygenase (IDO) systemic activity on c

192 The heme enzyme indoleamine 2,3-dioxygenase (IDO) was found to catalyze

193 In vivo blockade of indoleamine 2,3-dioxygenase (IDO) was performed, and its

194 In contrast, we found that the induction of indoleamine 2,3-dioxygenase (IDO) was required for the a

195 the tolerogenic tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) were analyzed using fl

196 Inflammation activates indoleamine 2,3-dioxygenase (IDO) which metabolizes tryp

197 ithelial infection by inducing expression of indoleamine 2,3-dioxygenase (IDO), a host enzyme with pr

198 sed antitumor response through inhibition of indoleamine 2,3-dioxygenase (IDO), a key tolerogenic enz

199 The expression of indoleamine 2,3-dioxygenase (IDO), a known immunosuppres

200 duct brassinin to be a moderate inhibitor of indoleamine 2,3-dioxygenase (IDO), a new cancer immunosu

201 Indoleamine 2,3-dioxygenase (IDO), a potent immunosuppre

202 Br-brassinin) are bioavailable inhibitors of indoleamine 2,3-dioxygenase (IDO), a pro-toleragenic enz

203 s to HDAC inhibitors increased expression of indoleamine 2,3-dioxygenase (IDO), a suppressor of DC fu

204 through pathogen-specific local induction of indoleamine 2,3-dioxygenase (IDO), a tryptophan cataboli

205 re treated with a pharmacologic inhibitor of indoleamine 2,3-dioxygenase (IDO), a tryptophan-cataboli

206 ad7-deficient DCs expressed higher levels of indoleamine 2,3-dioxygenase (IDO), an enzyme associated

207 at M. tuberculosis induced the expression of indoleamine 2,3-dioxygenase (IDO), an enzyme involved in

208 blot analysis, which indicated induction of indoleamine 2,3-dioxygenase (IDO), an enzyme that conver

209 One ISG candidate, indoleamine 2,3-dioxygenase (IDO), an IFN-gamma-induced

210 Similar to CTLA-4 and FoxP3, expression of indoleamine 2,3-dioxygenase (IDO), an immunosuppressive

211 Indoleamine 2,3-dioxygenase (IDO), an interferon gamma-i

212 sing T cells (CARTs) through the activity of indoleamine 2,3-dioxygenase (IDO), an intracellular enzy

213 nzymes, tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO), during its conversion

214 l-molecule immunotherapy agent that inhibits indoleamine 2,3-dioxygenase (IDO), encapsulated in the n

215 yptophan catabolism, initiated by the enzyme indoleamine 2,3-dioxygenase (IDO), is a critical partici

216 Although the tryptophan-degrading enzyme, indoleamine 2,3-dioxygenase (IDO), is a pivotal mediator

217 analytes-including plasma concentrations of indoleamine 2,3-dioxygenase (IDO), KYN, kynurenic acid (

218 ted reduced toxicity as reflected by induced indoleamine 2,3-dioxygenase (IDO), suggesting discreet a

219 induce an IFNgamma-driven induction of host indoleamine 2,3-dioxygenase (IDO), the first and rate-li

220 Indoleamine 2,3-dioxygenase (IDO), the first and rate-li

221 We studied the expression of indoleamine 2,3-dioxygenase (IDO), the first enzyme in t

222 n of innate immunity, induces high levels of indoleamine 2,3-dioxygenase (IDO), the rate-limiting enz

223 Indoleamine 2,3-dioxygenase (IDO), the rate-limiting enz

224 f expressing the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO), which allows them to

225 As tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO), which convert tryptop

226 Indoleamine 2,3-dioxygenase (IDO), which degrades trypto

227 C production of the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO), which depletes local

228 ations of RV-PV dysfunction with circulating indoleamine 2,3-dioxygenase (IDO)-dependent tryptophan m

229 ptophan oxidation products produced from the indoleamine 2,3-dioxygenase (IDO)-mediated kynurenine pa

230 te-limiting enzyme of tryptophan catabolism, indoleamine 2,3-dioxygenase (IDO).

231 uce the tryptophan (Trp)-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO).

232 ession of the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO).

233 l expression of the immunosuppressive enzyme indoleamine 2,3-dioxygenase (Ido).

234 s) up-regulate the immune-inhibitory enzyme, indoleamine 2,3-dioxygenase (IDO).

235 s a key pharmacophore in novel inhibitors of indoleamine 2,3-dioxygenase (IDO).

236 family of homologous enzymes, which includes indoleamine 2,3-dioxygenase (IDO).

237 LNs can express the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO).

238 his tolerance is the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO).

239 essed immunosuppressive levels of the enzyme indoleamine 2,3-dioxygenase (IDO).

240 expression of tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase (IDO).

241 in RA patients partly via the production of indoleamine 2,3-dioxygenase (IDO).

242 use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunos

243 oring of tryptophan (trp) metabolism through indoleamine 2.3-dioxygenase (IDO) has been previously pr

244 uced inducible nitric oxide synthase (iNOS), indoleamine-2,3-dioxygenase (IDO) and heme oxygenase (HO

245 Indoleamine-2,3-dioxygenase (IDO) and tryptophanyl-tRNA-

246 Expression of indoleamine-2,3-dioxygenase (IDO) by vascular endotheliu

247 The enzyme indoleamine-2,3-dioxygenase (IDO) catalyses degradation

248 t levo-1-methyl tryptophan (L-1MT) can block indoleamine-2,3-dioxygenase (IDO) expressed by human den

249 the tumor tissue by the rate-limiting enzyme indoleamine-2,3-dioxygenase (IDO) expressed in tumor cel

250 yptophan pools by gamma interferon-inducible indoleamine-2,3-dioxygenase (IDO) is believed to be the

251 ryptophan and kynurenine, metabolites of the indoleamine-2,3-dioxygenase (IDO) pathway.

252 roids augment MSC expression and activity of indoleamine-2,3-dioxygenase (IDO), a primary mediator of

253 Expression of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive

254 m the induction of type I IFN-alpha/beta and indoleamine-2,3-dioxygenase (IDO)-mediated immunosuppres

255 ting environment via induction of the enzyme indoleamine-2,3-dioxygenase (IDO).

256 ibitor of the tryptophan catabolizing enzyme indoleamine-2,3-dioxygenase (IDO).

257 ential target as the immunoregulatory enzyme indoleamine-2,3-dioxygenase (IDO).

258 Furthermore, while indoleamine 2,3-dioxygenase (IDO1) drives AhR activation

259 ession of the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO1) in human epithelial c

260 Indoleamine 2,3-dioxygenase (IDO1) inhibitors are specul

261 Indoleamine 2,3-dioxygenase (IDO1) is a heme enzyme that

262 Indoleamine 2,3-dioxygenase (IDO1) is a tryptophan (Trp)

263 Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO1) is an important mecha

264 he anti-inflammatory and anti-bacterial gene indoleamine 2,3-dioxygenase (IDO1) is dependent on STAT1

265 al burdens than control mice, underexpressed indoleamine-2,3-dioxygenase (Ido1) in lung endothelium a

266 in the promoter region of the gene encoding indoleamine-2,3-dioxygenase (IDO1) was found to be assoc

267 we show that untreated PDACs express minimal indoleamine-2,3-dioxygenase (IDO1); however, GVAX therap

268 on (IFN)-gamma induces the expression of the indoleamine 2, 3-dioxygenase (INDO) gene in human cells,

269 Indoleamine 2,3-dioxygenase (INDO) is the rate-limiting

270 f AhR ligands by microbiota that could limit indoleamine 2,3-dioxygenase induction and influence allo

271 Camptothesome co-load the indoleamine 2,3-dioxygenase inhibitor indoximod into its

272 ally sensitive to immunopharmacotherapy with indoleamine 2,3-dioxygenase inhibitors.

273 We measured indoleamine 2,3-dioxygenase, interleukin-6, and transfor

274 n (which is a known competitive inhibitor of indoleamine 2,3-dioxygenase) is a competitive inhibitor

275 ed during tryptophan metabolism initiated by indoleamine 2,3-dioxygenase, is known to induce T cell d

276 Abnormal tryptophan metabolism catalyzed by indoleamine 2,3-dioxygenase may play a prominent role in

277 ance of L-tryptophan transport for placental indoleamine 2,3-dioxygenase-mediated degradation of L-tr

278 nts both BCH and 1-methyl-tryptophan inhibit indoleamine 2,3-dioxygenase-mediated L-tryptophan degrad

279 e trophoblast to be a rate-limiting step for indoleamine 2,3-dioxygenase-mediated L-tryptophan degrad

280 his mechanism is dependent both on placental indoleamine 2,3-dioxygenase-mediated tryptophan degradat

281 cyte division was specifically suppressed by indoleamine 2,3-dioxygenase-mediated tryptophan depletio

282 ne (l-Kyn), which is supplied by a dedicated indoleamine-2,3-dioxygenase NanC encoded in the gene clu

283 also inhibited PIV3, including IFITM1, IDO (indoleamine 2,3-dioxygenase), PKR (protein kinase, RNA a

284 rs such as TGF-beta, CTLA-4, PD-1, ICOS, and indoleamine 2,3-dioxygenase play an important role in im

285 Indoleamine 2,3-dioxygenase plays a key role in local tr

286 FN-gamma synthesis by donor T cells inducing indoleamine 2,3-dioxygenase synthesis by donor pDCs limi

287 ane vesicles as part of a study on placental indoleamine 2,3-dioxygenase, the L-tryptophan-catabolisi

288 ending on IFNgamma signaling and mediated by indoleamine 2,3-dioxygenase to a constitutive mechanism

289 ence of interferon-gamma (known to stimulate indoleamine 2,3-dioxygenase) tryptophan but not threonin

290 including those combining PD1 blockade with indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase (

291 leged media, which related to A20 preventing indoleamine 2,3-dioxygenase upregulation in SMC.

292 Indoleamine 2,3-dioxygenase was expressed on background

293 explants was markedly reduced when placental indoleamine 2,3-dioxygenase was stimulated with interfer

294 a number of suppressive enzymes, among which indoleamine 2,3-dioxygenase was sufficient to inhibit an

295 ic cell accumulation, expression of IL-2 and indoleamine 2,3-dioxygenase were evident in TLR4 compare

296 ly produced by both cell populations, unlike indoleamine 2, 3-dioxygenase which was only produced fol

297 ophan limitation mediated by the host enzyme indoleamine 2,3-dioxygenase, which converts l-tryptophan

298 and primarily dependent on pDC expression of indoleamine 2,3-dioxygenase, which was induced through t

299 tor-kappaB, as well as the metabolic enzyme, indoleamine-2,3-dioxygenase, which breaks down tryptopha

300 uman (hIDO) and Shewanella oneidensis (sIDO) indoleamine 2,3-dioxygenases, Xanthomonas campestris (Xc